



Published in final edited form as:

Nat Genet. 2017 December ; 49(12): 1722–1730. doi:10.1038/ng.3978.

## Exome chip meta-analysis identifies novel loci and East Asian-specific coding variants contributing to lipid levels and coronary artery disease

A full list of authors and affiliations appears at the end of the article.

### Abstract

Most genome-wide association studies have been conducted in European individuals, even though most genetic variation in humans is seen only in non-European samples. To search for novel loci associated with blood lipid levels and clarify the mechanism of action at previously identified lipid loci, we examined protein-coding genetic variants in 47,532 East Asian individuals using an exome array. We identified 255 variants at 41 loci reaching chip-wide significance, including 3 novel loci and 14 East Asian-specific coding variant associations. After meta-analysis with > 300,000 European samples, we identified an additional 9 novel loci. The same 16 genes were identified by the protein-altering variants in both East Asians and Europeans, likely pointing to the functional genes. Our data demonstrate that most of the low-frequency or rare coding variants associated with lipids are population-specific, and that examining genomic data across diverse ancestries may facilitate the identification of functional genes at associated loci.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

Corresponding author; Cristen Willer, Division of Cardiovascular Medicine and Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, [cristen@umich.edu](mailto:cristen@umich.edu), Tel: 734-647-6018, Fax: 734-764-4142.

<sup>46</sup>A list of members and affiliations appears in the Supplementary Note.

<sup>47</sup>These authors jointly supervised this work

Dongfeng Gu, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China, [gdongfeng@vip.sina.com](mailto:gdongfeng@vip.sina.com), Tel: (8610) 68331752 Fax: (8610) 88363812

Pak Chung Sham, Department of Psychiatry, Centre for Genomic Sciences, The University of Hong Kong, Hong Kong, China, [pesham@hku.hk](mailto:pesham@hku.hk), Tel: (852) 22554486 Fax: (852) 28551345

URLs.

Genotype-Tissue Expression (GTEx) Portal, <http://www.gtexportal.org/home>

Genezoom, <http://genome.sph.umich.edu/wiki/Genezoom>

ExAC, <http://exac.broadinstitute.org>

RareMETALS, <http://genome.sph.umich.edu/wiki/RareMETALS>

RVTESTS, <http://genome.sph.umich.edu/wiki/RvTests>

RAREMETALWORKER, <http://genome.sph.umich.edu/wiki/RAREMETALWORKER>

### Author Contributions

**Drafting of the manuscript:** X.Lu, C.J.W, G.M.P, D.J.L., D.G., K.L.M. **Project coordination:** C.J.W., D.G., X.Lu, P.C.S., S.K., K.L.M., Y.E.C. **Central meta-analysis group:** X.Lu, D.J.L., G.M.P, H.Z. **eQTL analysis:** X.Lu, J.B.N. **DeltaSVM analysis:** X.Lu, W.Zhou. **Cohort data analyst:** X.Lu, G.M.P, D.J.L., Y.Wu, H.Z., J.Li, C.S.T., R.D., J.Long, X.G., C.N.S., Y.C., Y.Wang, C.Y.Y.C, Q.F., J.S., X.Y., W.Zhao, M.H., J.B.N. **Cohort genotyping:** W.Zhou, H.L., C.C.K., J.Liu, L.W., F.W., J.S., W.H. **Cohort phenotyping:** H.L., M.X., X.Liu, Y.Z., L.S., Y.G., Y.Hu, K.Y., J.H., Q.C., S.C., A.B.F, L.S.A., P.G., S.D., K.H., L.F. **Cohort Principal investigators:** X.Lu, W.H.S., S.S.C., A.B.F, L.S.A., P.G., S.D., R.V., Y.I.C., X.O.S., K.S.L.L, T.Y.W., S.K.G., Z.M., K.H., L.F., H.T., Y.Huo, C.C., Y.E.C., W.Zheng, E.S.T., W.G., X.Lin, W.H., G.A., S.K., K.L.M., T.W., P.C.S., D.G., C.J.W.

### Competing Financial Interests

The authors declare no competing financial interests.

## Introduction

Genome-wide association studies (GWAS) have revealed over 175 genetic loci contributing to lipid levels<sup>1–6</sup>, which are heritable risk factors for cardiovascular disease, fatty liver disease, age-related macular degeneration and type 2 diabetes<sup>7–9</sup>. However, most of the published lipid-associated variants fall in non-protein-coding regions of the genome, are without obvious biological significance, and explain only a small fraction of the heritability of lipid levels. The examination of low frequency and potentially functional variants, poorly captured by standard GWAS arrays, has the potential to pinpoint causal variants and genes for follow-up and functional analyses, therefore promoting translation of the finding of genetic studies into new therapeutic targets. For example, low-frequency coding variants in *PCSK9* lower plasma low density lipoprotein cholesterol (LDL-C), reduce risk of coronary artery disease (CAD), and have prompted the development of a new class of therapeutics<sup>10</sup>. Thus, we investigated the effect on lipid levels of the rare and low-frequency variants in the coding portion of the genome in an East Asian population, which has not been as extensively studied as the European population<sup>11–13</sup>.

We performed a meta-analysis of exome-wide association studies of blood lipid levels (high density lipoprotein cholesterol [HDL-C], LDL-C, triglycerides [TG], and total cholesterol [TC]) in a total of 47,532 East Asian samples that were genotyped using an exome array. We further integrated the exome array data for plasma lipids in over 300,000 individuals, primarily European ancestry (84%), conducted by the Global Lipids Genetics Consortium (GLGC). We aimed to determine whether novel or population-specific variants and genes influencing lipid levels could be identified in East Asian and multi-ancestry meta-analysis. Secondly, we aimed to determine if the protein-altering variants located in known lipid loci explained the association signal or were independent evidence of functional genes. And lastly, we examined whether exome data would implicate the same putatively functional genes in European and East Asian ancestries at lipid loci.

## Results

To improve the coverage for the low frequency variants in Asian populations and follow up various GWAS variants, approximately 60K custom content variants were added to the standard exome array. Among 319,272 variants passing quality control, 204,408 (64.0%) were polymorphic in the East Asian individuals, of which about 25% (n = 50,126) were from the custom content. Approximately 76.1% (n=155,566) of the polymorphic variants are annotated as nonsynonymous or loss of function (stop-gain, stop-loss and splice variants) (Supplementary Table 1). By determining the proportion of variants observed in ExAC East Asian samples (n = 4,327 individuals) that were successfully genotyped by the array, we estimated that the exome array captured a large fraction of common and low-frequency coding variants (71.15% and 72.59% for variants with minor allele frequency (MAF) >5% and MAF = 1–5%, respectively). Among rare coding variants identified in ExAC sequenced individuals, 59.91% (MAF = 0.1–1%) and 19.92% (two or more copies) were captured by the array. Therefore, the array provided good coverage for low-frequency and moderate coverage for rare coding variants in East Asians. In addition, we examined 76K polymorphic coding variants that were not available or monomorphic in ExAC East Asian samples.

## Discovery of novel variants associated with lipid levels

Our analysis identified three study-wide significant variants in three novel loci in East Asians, located at least 1 megabase from previously reported GWAS signals of lipid levels (Table 1). These include rs4377290 in *ACVR1C* (TC,  $P = 4.69 \times 10^{-8}$ ), rs7901016 in *MCU* (LDL-C,  $P = 5.12 \times 10^{-9}$ ), and the missense variant rs4883263 (encoding p.Ile342Val) in *CDI63* (HDL-C,  $P = 5.24 \times 10^{-11}$ ). Each of these three variants demonstrated evidence for association ( $P = 1.80 \times 10^{-3} \sim 6.68 \times 10^{-5}$ ) in over 300,000 GLGC individuals.

## Summary of association results

We assessed association of 110,986 polymorphic variants that had at least 20 minor alleles in 47,532 East Asian samples. Overall, we detected 255 variants (including 51 coding variants) at 41 loci that reached exome-wide significant association with one or more lipid trait ( $P < 4.5 \times 10^{-7}$ ), of which 3 loci have not been previously reported (Figure 1). Collectively, the overall variance in each lipid trait explained by exome-wide significant variants in East Asian samples was 5.97% for TC, 6.20% for LDL-C, 6.93% for HDL-C, and 6.89% for TG levels, respectively, of which 3.22%, 4.77%, 3.35% and 3.86% can be attributed to coding variants (Figure 2). Our results also showed that additional 7 known loci were associated with lipid levels at suggestive significance ( $P < 4.46 \times 10^{-6}$ , Bonferroni correction of 11,215 variants) (Supplementary table 2), and that, taken together they increased the trait variance explained to 6.08%~7.20%.

## Evaluation of known lipid signals

Among the 38 previously established lipid loci that reached significance, we identified a more significant candidate variant at 14 loci (Supplementary Table 3 and Figure 1), where the initially reported GWAS index variants showed no significant associations or were independent of previously identified associations in European populations ( $r^2 < 0.02$ ) (*APOB* and *APOE*), demonstrating allelic heterogeneity between East Asian and European ancestries. The lead variants in the remaining 24 loci were the same as or strongly related ( $r^2 > 0.69$ ) to the reported GWAS index variants from previous studies in primarily European samples. Sequential conditional analyses revealed that 12 loci with evidence of association exhibited two or more significant signals (Supplementary Table 4). For example, a novel missense variant (rs2075260, encoding p.Val214Ile) at *ACACB* was detected and largely independent of the originally reported GWAS index rs7134594 at *MVK* ( $r^2 = 0.01$ )<sup>2</sup>, representing novel association not previously reported. The GWAS index rs7134594 could be explained by another missense variant (rs9593 p.Met239Lys) at *MMAB* (conditional  $P = 0.73$ ).

For gene-base analysis, nine genes (*PCSK9*, *EVI5*, *HMGCR*, *CD36*, *APOA1*, *PCSK7*, *CETP*, *LDLR* and *PPARA*) reached gene-based significance ( $P < 2.8 \times 10^{-6}$ ) with lipid levels (Supplementary Figure 1 and Supplementary Table 5), however, no new genes were identified by gene-based analyses that weren't already highlighted by single variant tests.

## Putative functional coding variants at the known loci

Identifying coding variants in known loci has the potential to help pinpoint causal genes. We observed that the protein-altering variants are more likely to have strong effect sizes on lipid

levels (Figure 3 and Supplementary Table 6), compared to the non-coding variants significantly associated with lipid levels. Ten coding variants in eight genes showed strong effects on lipid levels (beta range from 0.20 to 1.17 SD units), and 8 were low-frequency or rare variants (MAF < 3%). We next sought to quantify what proportion of GWAS loci might be due to a protein-altering variant, implicating a candidate functional gene. We make the reasonably well-supported assumption that a protein-altering variant, if the top signal, explains the signal, or is independent of the original signal, is the most likely causal variant for each region<sup>14–16</sup>. Among the 38 known loci showing association evidence at study-wide significance, 12 loci harbored a protein-altering variant that exhibited strongest association with lipid levels, while 4 loci have a protein-altering variant that was not the top signal but could explain the association of the reported index variant (Supplementary Table 7 and Figure 1). In 8 of these 16 loci (*PCSK9*, *EVI5*, *CD36*, *MMAB*, *ALDH2*, *SLC12A4*, *LDLR*, and *PPARA*), the previously identified lead variants in European populations did not reach exome-wide significance. In the remaining 8 loci (*GCKR*, *MLXIPL*, *HNFA1*, *LPL*, *ABO*, *GPAM*, *PMFBPI*, and *TM6SF2*), the GWAS index variant in each locus (*P* values range from  $4.86 \times 10^{-8}$  to  $1.26 \times 10^{-62}$ ) is in strong LD with the corresponding protein-altering variant ( $r^2 > 0.68$ ) and does not remain significant after accounting for the effect of the protein-altering variant (conditional *P* values > 0.01), suggesting that the index variant might act as a proxy for the functional protein-altering variant. Together, 42.1% (16/38) of loci appear to have a protein-altering variant that could account for the original association signal. In addition, we identified 15 protein-altering variants in 9 genes (*APOB*, *HMGCR*, *ABCA1*, *APOA1-APOA5*, *ACACB*, *CETP*, *PKD1L3*, *LIPG*, and *APOE*) that were independent of the original signal but may highlight functional genes in the region. All of these putative functional variants may point to functional candidate genes: either well-established causal genes (such as the genes that cause Mendelian dyslipidemias (Supplementary Table 8)) or to potential new candidate genes (*MMAB*, *ACACB*, *SLC12A4*, and *PMFBPI*). In total, the 31 protein-altering variants in the known loci may point to 25 candidate functional lipid genes.

### Association with coronary artery disease

To further evaluate whether the novel variants and putative functional variants in known regions identified in our samples also influenced CAD risk, we tested for association in 28,899 Chinese individuals with and without coronary disease (9,661 CAD cases and 18,558 controls) and in the largest publicly available CAD GWAS analyses (CARDIoGRAMplusC4D) of ~185,000 CAD cases and controls<sup>17</sup> (Supplementary Table 9). For the novel non-coding variant near *MCU* (rs7901016), the C allele associated with lower LDL-C was similarly associated with reduced risk for CAD in Chinese samples (OR = 0.94, 95% CI = 0.90–0.98, *P* =  $2.8 \times 10^{-3}$ ) and CARDIoGRAMplusC4D (OR = 0.94, 95% CI = 0.91–0.98, *P* =  $4.55 \times 10^{-4}$ ). Among the 31 putative functional coding variants in the known regions, all the 20 non-HDL-C related variants displayed a consistent direction of effect between lipid traits and CAD. 15 out of 20 showed nominal significance (*P* < 0.05) in Chinese or CARDIoGRAMplusC4D CAD data, whereas 7 variants in *PCSK9*, *APOB*, *LDLR*, *APOE*, *HNFA1*, and *APOA5* displayed significant associations even after accounting for multiple testing (*P*-value range from  $5.95 \times 10^{-4}$  to  $8.17 \times 10^{-11}$  < 0.05/31). In particular, nearly all of the LDL-associated coding variants demonstrated association with

CAD, and the strengths of effect on CAD risk and LDL-C were highly correlated ( $r^2 = 0.78$ ,  $P = 3.3 \times 10^{-4}$ , Supplementary Figure 2).

### Novel loci identified by East Asian and GLGC samples

An exome-wide association screen for plasma lipids in >300,000 individuals genotyped by the exome array was conducted in parallel by the Global Lipids Genetics Consortium. The majorities (84%) of the participants were of European ancestry, and only 2.3% were East Asian. We further carried out large-scale trans-ancestry meta-analysis in our East Asian and GLGC samples, being careful to include overlapping samples only once, to seek both novel and population-specific genetic variants for lipid levels.

In the combined GLGC and East Asian samples, 9 additional variants showed significant associations ( $P < 2.1 \times 10^{-7}$ , Bonferroni correction of 242,289 variants analyzed in GLGC) with at least one lipid trait, that were not significant in either the East Asian or GLGC analyses. All of them are common (MAF > 0.05 in both East Asian and GLGC), including 4 coding variants (Table 2 and Supplementary Figure 3): *FAM114A2* (p.Gly122Ser, HDL-C,  $P = 1.74 \times 10^{-7}$ ), *MGAT1* (p.Leu435Pro, HDL-C,  $P = 9.36 \times 10^{-8}$ ), *ASCC3* (p.Leu146Phe, LDL-C,  $P = 5.84 \times 10^{-8}$ , TC,  $P = 5.22 \times 10^{-9}$ ), *PLCE1* (p.Arg1575Pro, TC,  $P = 9.92 \times 10^{-8}$ ).

### Joint analysis of the novel signals with additional samples

To strengthen support for association, we performed *in silico* replication of significant variants in three additional independent genome-wide datasets, comprising a combined total of ~160,000 individuals from the Nord-Trøndelag Health Study (HUNT)<sup>18</sup>, GLGC GWAS samples<sup>2</sup>, and Chinese lipids GWAS study<sup>19</sup>. We found that the associations of 12 novel variants became more significant and reached genome-wide significance in the joint analysis ( $P$  values range from  $2.99 \times 10^{-8}$  to  $7.62 \times 10^{-15}$ ) (Supplementary Table 10).

### Coding variants point to the same genes across ancestries

We further evaluated whether these variants identified in East Asian were also defined as putative functional variants in GLGC samples (Supplementary Table 11). We found that both East Asian and GLGC samples pointed to the same nine functional genes, but had different associated variants in each ancestry (Table 3). The eight coding variants (MAF range from 0.004% to 15.9%) at *PCSK9*, *CD36*, *ABCA1*, *CETP*, *PMFBP1*, *LIPG*, *LDLR*, and *PPARA* identified by GLGC showed lower minor allele frequencies (MAF range from 0 to 2.57%) in the East Asian samples and, thus, displayed no significance or only suggestive significance (*CETP*). Conversely, the coding variants at *PCSK9*, *APOB*, *CD36*, *CETP*, *LDLR* and *PPARA* identified in East Asian (MAF range from 0.094% to 12.45%) also had lower minor allele frequencies in GLGC (MAF range from 0.001% to 0.20%). In addition, the same putatively functional coding variants and genes at seven loci (*GCKR*, *MLXIPL*, *LPL*, *GPAM*, *HNF1A*, *TM6SF2*, and *APOE*) were identified in both East Asian and GLGC samples, with similar common minor allele frequencies (Table 4).

### East Asian-specific association signals

We next attempted to identify variants that were associated with lipids in East Asian samples only. Within the known lipid loci, 363 independent variants were identified by sequential conditional analyses in GLGC exome-wide association studies (Supplementary Table 11). After conditioning on the independent variants in the corresponding loci, we identified 14 independent coding variant associations at 11 loci in East Asian samples with conditional  $P$  values  $< 4.5 \times 10^{-7}$  (Table 5, Figure 1 and 3). Interestingly, all 14 East Asian-specific variants are included in the list of the putative functional variants we identified. Eight of these loci (*EVI5*, *APOB*, *HMGCR*, *CD36*, *APOA1*, *CETP*, *LDLR*, and *PPARA*) harbored at least one low-frequency or rare independent coding variant (MAF range from 4.21% to 0.03%). All of these variants are either monomorphic or have a frequency at least 1 order of magnitude lower in Europeans and, thus, showed only suggestive significance in ~ 300,000 GLGC individuals.

### Discussion

This study represents the largest discovery effort for coding variation that influences lipid levels in the East Asian population, enabling us to systemically evaluate protein-altering variants that identify candidate functional genes. Meta-analyses in East Asian and multi-ancestry samples using an exome-chip genotyping array identified twelve novel loci, five of which harbored non-synonymous variants. In the 38 known loci that were replicated, we identified 31 protein-altering variants that likely point to 25 functional lipid genes. Moreover, the same 16 putative functional genes were identified by significant association with protein-altering variants in both European and East Asian samples--at 9 of those genes by identifying independent protein-altering variants in the two ancestries.

Among the novel genetic loci identified, several have been implicated in cardiovascular and metabolic phenotypes, which may provide mechanistic insight into the regulation of lipid levels and potential targets for treatments. The significant novel variant associated with both lipids and CAD is located in intron of *MCU*. *MCU* encodes mitochondrial inner membrane calcium uniporter that mediates calcium uptake into mitochondria. It has been found that mitochondrial calcium plays an important role in the regulation of metabolism in the heart<sup>20</sup>. *CD163* encodes a macrophage specific receptor involved in the clearance and endocytosis of hemoglobin-haptoglobin complexes by macrophages. Soluble CD163 was recently proposed as a biomarker of the well-known variables metabolic syndrome, including HDL-cholesterol<sup>21</sup>. *ACVR1C* encodes activin receptor-like kinase 7 (ALK7), one of the type I transforming growth factor- $\beta$  receptors. ALK7 has recently been demonstrated to play an important role in the maintenance of metabolic homeostasis<sup>22</sup>. ALK7 is highly expressed in adipose tissue of humans and is correlated with body fat and lipids. The ALK7 dysfunction could cause increased lipolysis in adipocytes and leads to decreased fat accumulation. *MGAT1* encodes Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,2-N-Acetylglucosaminyltransferase, which is involved in the synthesis of protein-bound and lipid-bound oligosaccharides. It has been found that the variant in *MGAT1* was associated with body weight and obesity<sup>23</sup>. Of note, *CD163* and *PDGFC* were also found to be associated with lipid levels by the East Asian lipids GWAS meta-analysis since our

manuscript was submitted<sup>24</sup>. To further clarify the possible transcriptional mechanisms underlying the identified loci in associations with lipids, we investigated the relationships of the novel variants and proxies with expression quantitative trait loci (eQTLs) using the GTEx eQTL browser. Significant cis-eQTLs effects in human tissues were found at five loci at a significance of  $P < 4.5 \times 10^{-7}$  (Supplementary Table 12). We further predicted putatively regulatory variants in seven novel noncoding regions in 81 cell type lines using deltaSVM scores<sup>25</sup>, and found that the variants in *PDGFC*, *LOC100996634*, and *MCU* had high regulatory potential with extreme deltaSVM scores greater than 10 in absolute value (Supplementary Figure 4).

Our data provided a more comprehensive understanding of the genetic architecture of lipid susceptibility by discovering novel lipid genes and revealing allelic heterogeneity across different ancestry populations. We detected multiple independent association signals or new lead variants in known lipid-associated loci that frequently displayed no or moderate linkage disequilibrium (LD) with the corresponding GWAS index variants in European populations. Specially, we identified 14 East Asian-specific variants that could not be explained by all the independent variants in the corresponding loci identified by GLGC samples. Our study demonstrated the benefits of distinct LD patterns between ancestry groups in dissecting validated loci. We also found substantial inter-ancestry differences in the identification of rare coding variants across populations, which may have been subjected to natural selection during human evolution or genetic drift. All the low-frequency or rare functional coding variants identified in East Asians (MAF range from 0.03% to 4.21%) appeared to be population-specific, and were monomorphic or not present in 1000 Genomes European individuals, this allelic heterogeneity across different ancestry populations have been partly reported<sup>6,11</sup>. However, we observed that these rare variants were not monomorphic in over 300,000 GLGC individuals, but had 15 to 160-fold lower frequencies (MAF range from 0.001% to 0.15%) in Europeans than East-Asians (Supplementary Table 13 and Supplementary Figure 5), with little power to detect association in Europeans. Similarly, the low-frequency and rare coding variants identified in GLGC samples were extremely rare or monomorphic in East Asian samples (Supplementary Figure 6 and Supplementary Table 11). Overall, our finding demonstrated that rare and low frequency coding variants are more likely to be population-specific, which underscores the value of discovering ancestry-specific rare variants in diverse populations, particularly for low frequency variation.

Since most GWAS index variants are located in non-coding regions, the identification of associated protein-coding variants may allow us to prioritize functional genes and variation. Among the 38 known loci that reached chip-wide significance in our data, coding variants at 16 loci (42.1%) were found to completely account for the original association signal. At an additional 9 loci, an independent protein-altering variant indicated a likely functional gene. The coding variants are more likely to have consistent effect sizes across ethnic groups compared to non-coding variants. For the GWAS index variants that could not be replicated in East Asian samples, the effect sizes were poorly correlated with those observed in Europeans. In contrast, the effect sizes of the putatively-functional coding variants in the same loci are strongly related across ethnic groups (Supplementary Figure 7). Trans-ancestry comparison provided additional credible evidence to support the same 16 genes as putative functional genes. The functional genes pointed to by coding variants are either well-known

genes or genes with previously unknown roles in lipid metabolism (such as *GPAM* and *PMFBPI*), which may be good candidates for functional assessment. More importantly, we found the effects of these putative functional coding variants on LDL cholesterol, triglyceride, and total cholesterol were highly correlated with the effect on CAD, but the effect on HDL cholesterol levels were not correlated with CAD. Our findings are consistent with the recent genetic studies that both LDL cholesterol and triglyceride levels but not HDL cholesterol levels are causally related to CAD risk<sup>26–29</sup>.

This large-scale exome wide association study allowed us to detect a larger number of low-frequency and rare variants, 30% of which were not polymorphic in the previous exome-wide study involving 12,685 Chinese individuals<sup>11</sup>. Nonetheless, the exome array offered moderate coverage for rare variants observed in ExAC East Asian samples. Power calculations indicated that the available sample size provided 80% power to detect variants with effect size of 0.27 s.d. and MAF as low as 0.5% at  $P < 4.5 \times 10^{-7}$ . However, we had considerably less power to evaluate extremely rare variants (MAF < 0.1%). Studies in larger sample sizes and of sequenced samples are therefore needed to fully investigate associations of rare variants with lipid levels.

In conclusion, we identified 12 new loci associated with lipid levels. We also identified coding variants that highlight 25 likely functional genes at previously known loci, including several with previously undiscovered roles in lipids. We also found an abundance of population specific coding variant associations that underlie lipid traits, highlighting the importance of including individuals of diverse ancestry background. At the same time, our data demonstrate that integrating genomic data across diverse ancestry groups may enable us to determine functional variants and genes for further functional study.

## Methods

### Study cohorts

Twenty three studies including both population-based studies and case-control studies of coronary artery disease (CAD) and type 2 diabetes (T2D) were genotyped with the Illumina HumanExome array resulting in a total of 47,532 participants, all of whom were of East Asian ancestry (Supplementary Table 14). All participants provided written informed consent, and ethics approval for their data generation and analyses was individually obtained for each contributing study. The relevant human genetic data was also approved by Ministry of Science and Technology of China. For GLGC exome study, the studies contributed association results for exome chip genotypes and plasma lipid levels (Supplementary notes and Supplementary Table 15).

### Phenotypes

For most East-Asian subjects (83%), TC, HDL-C, and TG were measured at > 8 hours of fasting. LDL-C levels were directly measured in 18 studies (88% of total study individuals) and were estimated using the Friedewald formula in the remaining studies, with missing values assigned to individuals with triglycerides >400 mg/dl. We adjusted the TC values for individuals on lipid-lowering medication by replacing their TC values by TC/0.8 with lipid



medication status available. If measured LDL-C was available in a study, the treated LDL-C value was divided by 0.7. No adjustment for individuals using medication was made for HDL-C and TG.

### Exome array genotyping and quality control

All study participants were genotyped on the HumanExome Bead-Chip (Illumina), and most cohorts (83%) also included the custom Asian Vanderbilt content. This custom content was added to the standard Illumina HumanExome BeadChip to improve the coverage of low frequency variants in Asian populations. The variants were selected from 1077 (581 Chinese women and 496 Singapore Chinese) whole exome sequenced East Asian samples generously provided by Wei Zheng and Jianjun Liu<sup>30</sup>. Additional approximately 29K common variants were added to the array including previously identified GWAS variants selected from the GWAS catalogue. Genotype calling was performed with GenTrain version 2.0 in GenomeStudio V2011.1 (Illumina) in combination with zCall version 2.2<sup>31</sup>. Within each study, individuals with low genotype completion rates, individuals expressing gender mismatches or a high level of heterozygosity, and related individuals, and PCA outliers were excluded from further analysis (Supplementary Table 16). In addition, variants that did not meet the 95% or 98% genotyping threshold or showed deviation from the Hardy-Weinberg equilibrium were removed.

### Statistical analyses

Within each cohort, HDL-C, LDL-C, TG and TC measurements were transformed using the inverse normal distribution after adjustment of each trait for age, age<sup>2</sup>, and study-specific covariates, including principal components in order to account for population structure. In studies ascertained on diabetes or cardiovascular disease status, cases and controls were analyzed separately.

We performed both single variant and gene-level association tests. Single variant analyses in each cohort were carried out using either RAREMETALWORKER or RVTESTS<sup>32</sup>, both of which generate single variant score statistics and their covariance matrix between single marker statistics. The test statistics, as visualized in a quantile–quantile plot, appeared well-calibrated (Supplementary Figure 8). Gene-based tests were restricted to variants that were predicted to alter the coding sequence of the gene product (defined as missense, stop-gain, stop-loss, or splice-site variants) in order to enhance the likelihood of identifying causal variants and to reduce the multiple testing burden. For each trait, we ran four gene-based tests: a variable threshold burden test with a MAF cutoff of <5% or <1% and a sequence kernel association test (SKAT) with a MAF cutoff of <5% or <1%. Next, the meta-analyses of single variant and gene-level association tests were performed using RAREMETALS<sup>33</sup> for HDL-C, LDL-C, TC and TG. For single variants, we applied a significance threshold of  $P < 4.5 \times 10^{-7}$ , corresponding to a Bonferroni correction for 110,986 polymorphic variants that had at least 20 minor alleles. For gene-level tests, we used a significance threshold of  $P < 2.8 \times 10^{-6}$ , corresponding to a Bonferroni correction for 17,614 gene-level tests.

To identify putative functional coding variants accounting for the effects at known lipid loci, we performed reciprocal conditional analyses to control for the effects of known lipid

GWAS or coding variants. Loci where the initial lead variant had conditional  $P > 0.01$  were considered to be explained by the variants used in the conditional analyses. To dissect East Asian-specific association signals in the reported loci, we also performed conditional association analysis for variants within 1MB of each locus using covariance matrices between single variant association statistics. Details of the methods can be found in Liu et al.<sup>32</sup>. To evaluate whether two or more independent association signals, we performed sequential conditional association analyses using the lead variant at each locus as a covariate until results after conditional analysis were no longer significant ( $P > 4.5 \times 10^{-7}$ ). We estimated the linkage disequilibrium (LD) metric  $r^2$  using the cohort-combined variants and LD matrices. LD for variants not included on the exome array was estimated from the 1000 Genomes Project East Asian individuals.

To further assess whether the identified functional coding variants also relate to coronary artery disease (CAD), we tested their associations with CAD in PUUMA-MI<sup>11</sup>, HKU-TRS, HuCAD<sup>34</sup>, and two GWAS samples<sup>35</sup> (the Beijing Atherosclerosis Study (BAS) and the China Atherosclerosis Study (CAS)) involving 9,661 CAD cases and 18,558 controls. The effect estimates and s.e. were meta-analysed using METAL by the fixed-effect inverse-variance method<sup>36</sup>. We also looked up the CAD association in the largest publicly available CAD GWAS analyses (CARDIoGRAMplusC4D) of ~185,000 CAD cases and controls<sup>17</sup>.

### In silico Replication Samples

The in silico replication study was conducted using additional independent individuals of European ancestry from the HUNT study<sup>18</sup> and GLGC GWAS<sup>2</sup>, and Chinese subjects from Chinese lipids GWAS<sup>19</sup>. HUNT is a population-based cohort of 62,168 individuals with genome-wide genotypes (Illumina Human CoreExome), imputation from the Haplotype Reference Consortium panel, and non-fasting lipid phenotypes. The Chinese lipids GWAS was a meta-analysis consisting of over 13,000 Han Chinese who underwent standardized collection of blood lipid measurements in five independent genome wide association studies. These studies included the China Atherosclerosis Study (CAS), the Beijing Atherosclerosis Study (BAS), Genetic Epidemiology Network of Salt-Sensitivity (GenSalt) study<sup>37</sup>, and the China Atherosclerosis Study phase II (CAS-II).

### Heritability and proportion of variance explained estimates

We estimate the proportion of variance explained by the set of independently associated variants. Joint effects of variants in a locus were approximated by  $\hat{\beta}_{JOINT} = \mathbf{V}_{META}^{-1} \vec{U}_{META}$ , where  $\vec{U}_{META}$  is single variant score statistics and  $\mathbf{V}_{META}^{-1}$  is the covariance matrix between them. Covariance between single variant genetic effects were approximated by the inverse of the variance-covariance matrix of score statistics, i.e.  $\mathbf{V}_{META}^{-1}$ . The explained phenotype variance by independently associated variants in a locus is given by  $\hat{\beta}_{JOINT}^{cov(G)} \hat{\beta}_{JOINT}$ .

## Annotation

Variants were annotated as missense, splice, stop-gain/loss, synonymous or noncoding using ANNOVAR (version 2012-05-25)<sup>38</sup>. Variant identifiers and chromosomal positions are listed with respect to the hg19 genome build.

## DeltaSVM analysis

DeltaSVM uses a gapped k-mer support vector machine to estimate the effect of a variant in a cell-type-specific manner<sup>25</sup>. Precomputed weights were available from a total of 222 ENCODE DHS samples—99 from the Duke University (Duke) set and 123 from the University of Washington (UW) set<sup>39</sup>. For the current study, genetic variants were scored for deltaSVM in 81 cell lines from four tissues (blood, blood vessel, heart and liver). For each of the seven novel noncoding regions, all proxies ( $r^2 > 0.8$ ) were identified using data from 1000 genome.

## Data Availability

Summary statistics have been made available for download from <http://csg.sph.umich.edu/abecasis/public/lipids2017EastAsian>. Additional supporting data are provided in the supplementary material.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Authors

Xiangfeng Lu<sup>1,2,3</sup>, Gina M Peloso<sup>4,5,6</sup>, Dajiang J. Liu<sup>7</sup>, Ying Wu<sup>8</sup>, He Zhang<sup>2,3</sup>, Wei Zhou<sup>9</sup>, Jun Li<sup>10</sup>, Clara Sze-man Tang<sup>11</sup>, Rajkumar Dorajoo<sup>12</sup>, Huaixing Li<sup>13</sup>, Jirong Long<sup>14</sup>, Xiuqing Guo<sup>15</sup>, Ming Xu<sup>16</sup>, Cassandra N. Spracklen<sup>8</sup>, Yang Chen<sup>17</sup>, Xuezhen Liu<sup>9</sup>, Yan Zhang<sup>18</sup>, Chiea Chuen Khor<sup>12,19,20</sup>, Jianjun Liu<sup>12</sup>, Liang Sun<sup>13</sup>, Laiyuan Wang<sup>1</sup>, Yu-Tang Gao<sup>21</sup>, Yao Hu<sup>13</sup>, Kuai Yu<sup>10</sup>, Yiqin Wang<sup>13</sup>, Chloe Yu Yan Cheung<sup>22</sup>, Feijie Wang<sup>13</sup>, Jianfeng Huang<sup>1,23</sup>, Qiao Fan<sup>20,24</sup>, Qiuyin Cai<sup>14</sup>, Shufeng Chen<sup>1</sup>, Jinxiu Shi<sup>25</sup>, Xueli Yang<sup>1</sup>, Wanting Zhao<sup>20</sup>, Wayne H.-H. Sheu<sup>26</sup>, Stacey Shawn Cherny<sup>27,28,29</sup>, Meian He<sup>10</sup>, Alan B. Feranil<sup>30,31</sup>, Linda S. Adair<sup>32</sup>, Penny Gordon-Larsen<sup>32,33</sup>, Shufa Du<sup>32,33</sup>, Rohit Varma<sup>34</sup>, Yii-Der I da Chen<sup>15</sup>, XiaoOu Shu<sup>14</sup>, Karen Siu Ling Lam<sup>22,35,36</sup>, Tien Yin Wong<sup>19,24,37,38</sup>, Santhi K. Ganesh<sup>2,3</sup>, Zengnan Mo<sup>17</sup>, Kristian Hveem<sup>39,40,41</sup>, Lars Fritsche<sup>39,40,42</sup>, Jonas Bille Nielsen<sup>2</sup>, Hung-fat Tse<sup>22,35,43</sup>, Yong Huo<sup>18</sup>, Ching-Yu Cheng<sup>20,38,44</sup>, Y. Eugene Chen<sup>2</sup>, Wei Zheng<sup>14</sup>, E Shyong Tai<sup>24,37,45</sup>, Wei Gao<sup>16</sup>, Xu Lin<sup>13</sup>, Wei Huang<sup>25</sup>, Goncalo Abecasis<sup>42</sup>, GLGC Consortium<sup>46</sup>, Sekar Kathiresan<sup>4,5</sup>, Karen L. Mohlke<sup>8</sup>, Tangchun Wu<sup>10</sup>, Pak Chung Sham<sup>27,28,29,47</sup>, Dongfeng Gu<sup>1,47</sup>, and Cristen J Willer<sup>2,3,9,47</sup>

## Affiliations

<sup>1</sup>Department of Epidemiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

<sup>2</sup>Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA

<sup>3</sup>Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA

<sup>4</sup>Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA

<sup>5</sup>Program in Medical and Population Genetics, Broad Institute, Cambridge Center, Cambridge, MA, USA

<sup>6</sup>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA

<sup>7</sup>Department of Public Health Sciences, Institute of Personalized Medicine, Penn State University, University Park, PA, USA

<sup>8</sup>Department of Genetics, University of North Carolina, Chapel Hill, NC, USA

<sup>9</sup>Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA

<sup>10</sup>MOE Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China

<sup>11</sup>Department of Surgery, Li KaShing Faculty of Medicine, The University of Hong Kong, Hong Kong, China and Dr. Li Dak-Sum Research Centre, The University of Hong Kong – Karolinska Institutet Collaboration in Regenerative Medicine, Hong Kong, China

<sup>12</sup>Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore

<sup>13</sup>Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and University of the Chinese Academy of Sciences, Shanghai, China

<sup>14</sup>Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA

<sup>15</sup>Institute for Translational Genomics and Population Sciences, LABioMed at Harbor-UCLA Medical Center, Los Angeles, CA, USA

<sup>16</sup>Department of Cardiology, Institute of Vascular Medicine, Peking University Third Hospital, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China

<sup>17</sup>Center for Genomic and Personalized Medicine, Medical Scientific Research Center and Department of Occupational Health and Environmental Health, School of Public Health, Guangxi Medical University, Nanning, Guangxi, China

<sup>18</sup>Department of Cardiology, Peking University First Hospital, Beijing, China

<sup>19</sup>Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore

<sup>20</sup>Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore

<sup>21</sup>Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

<sup>22</sup>Department of Medicine, the University of Hong Kong, Hong Kong, China

<sup>23</sup>The 3rd Affiliated Hospital of Shenzhen University, Shenzhen, China

<sup>24</sup>Duke-National University of Singapore Graduate Medical School, Singapore, Singapore

<sup>25</sup>Department of Genetics, Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, China

<sup>26</sup>Division of Endocrine and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

<sup>27</sup>Department of Psychiatry, the University of Hong Kong, Hong Kong, China

<sup>28</sup>Centre for Genomic Sciences, Li KaShing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

<sup>29</sup>State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong, China

<sup>30</sup>USC-Office of Population Studies Foundation, University of San Carlos, Cebu City, Philippines

<sup>31</sup>Department of Anthropology, Sociology, and History, University of San Carlos, Cebu City, Philippines

<sup>32</sup>Department of Nutrition, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA

<sup>33</sup>Carolina Population Center, University of North Carolina, Chapel Hill, NC, USA

<sup>34</sup>USC Eye Institute, Department of Ophthalmology, Keck School of Medicine of the University of Southern California, CA, USA

<sup>35</sup>Research Centre of Heart, Brain, Hormone and Healthy Aging, Li KaShing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

<sup>36</sup>State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China

<sup>37</sup>Saw Swee Hock School of Public Health, National University Health System, National University of Singapore, Singapore, Singapore

<sup>38</sup>Department of Ophthalmology, National University of Singapore, Singapore, Singapore

<sup>39</sup>HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway

<sup>40</sup>K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health, Norwegian University of Science and Technology, Trondheim, Norway

<sup>41</sup>Department of Medicine, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway

<sup>42</sup>Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA

<sup>43</sup>Hong Kong-Guangdong Joint Laboratory on Stem Cell and Regenerative Medicine, the University of Hong Kong, Hong Kong, China

<sup>44</sup>Ophthalmology and Visual Sciences Academic Clinical Programme, Duke-NUS Medical School, Singapore, Singapore

<sup>45</sup>Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore

## Acknowledgments

We thank all the participants of this study for their contributions. X. Lu is supported by the National Science Foundation of China (81422043, 91439202, 81370002, and 81773537) and CAMS Innovation Fund for Medical Sciences (2016-I2M-1-009, 2016-I2M-1-011). C.J.W. is supported by HL135824 and S.K. and C.J.W. are supported by HL127564. Additional acknowledgments of funding sources for the primary studies are provided in the Supplementary Note.

## References


1. Teslovich TM, et al. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature*. 2010; 466:707–13. [PubMed: 20686565]
2. Willer CJ, et al. Discovery and refinement of loci associated with lipid levels. *Nat Genet*. 2013; 45:1274–83. [PubMed: 24097068]
3. Surakka I, et al. The impact of low-frequency and rare variants on lipid levels. *Nat Genet*. 2015; 47:589–97. [PubMed: 25961943]
4. Asselbergs FW, et al. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. *Am J Hum Genet*. 2012; 91:823–38. [PubMed: 23063622]
5. Kim YJ, et al. Large-scale genome-wide association studies in East Asians identify new genetic loci influencing metabolic traits. *Nat Genet*. 2011; 43:990–995. [PubMed: 21909109]
6. Wu Y, et al. Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. *PLoS Genet*. 2013; 9:e1003379. [PubMed: 23555291]
7. Lambert NG, et al. Risk factors and biomarkers of age-related macular degeneration. *Prog Retin Eye Res*. 2016S1350–9462(16)30012-X
8. Herder C, Kowall B, Tabak AG, Rathmann W. The potential of novel biomarkers to improve risk prediction of type 2 diabetes. *Diabetologia*. 2014; 57:16–29. [PubMed: 24078135]
9. Wierzbicki AS, Oben J. Nonalcoholic fatty liver disease and lipids. *Curr Opin Lipidol*. 2012; 23:345–52. [PubMed: 22617751]
10. Kathiresan S. A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. *N Engl J Med*. 2008; 358:2299–300. [PubMed: 18499582]
11. Tang CS, et al. Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese. *Nat Commun*. 2015; 6:10206. [PubMed: 26690388]

12. Peloso GM, et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. *Am J Hum Genet.* 2014; 94:223–32. [PubMed: 24507774]
13. Lange LA, et al. Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. *Am J Hum Genet.* 2014; 94:233–45. [PubMed: 24507775]
14. Holmen OL, et al. Systematic evaluation of coding variation identifies a candidate causal variant in *TM6SF2* influencing total cholesterol and myocardial infarction risk. *Nat Genet.* 2014; 46:345–51. [PubMed: 24633158]
15. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of *IFIH1*, a gene implicated in antiviral responses, protect against type 1 diabetes. *Science.* 2009; 324:387–9. [PubMed: 19264985]
16. Sanna S, et al. Fine mapping of five loci associated with low-density lipoprotein cholesterol detects variants that double the explained heritability. *PLoS Genet.* 2011; 7:e1002198. [PubMed: 21829380]
17. Nikpay M, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet.* 2015; 47:1121–30. [PubMed: 26343387]
18. Krokstad S, et al. Cohort Profile: the HUNT Study, Norway. *Int J Epidemiol.* 2013; 42:968–77. [PubMed: 22879362]
19. Lu X, et al. Genetic Susceptibility to Lipid Levels and Lipid Change Over Time and Risk of Incident Hyperlipidemia in Chinese Populations. *Circ Cardiovasc Genet.* 2016; 9:37–44. [PubMed: 26582766]
20. Williams GS, Boyman L, Lederer WJ. Mitochondrial calcium and the regulation of metabolism in the heart. *J Mol Cell Cardiol.* 2015; 78:35–45. [PubMed: 25450609]
21. Parkner T, Sørensen LP, Nielsen AR, Fischer CP, Bibby BM, Nielsen S, Pedersen BK, Møller HJ. Soluble CD163: a biomarker linking macrophages and insulin resistance. *Diabetologia.* 2012; 55:1856–62. [PubMed: 22450890]
22. Carlsson LM, et al. *ALK7* expression is specific for adipose tissue, reduced in obesity and correlates to factors implicated in metabolic disease. *Biochem Biophys Res Commun.* 2009; 382:309–14. [PubMed: 19275893]
23. Johansson A, et al. Linkage and genome-wide association analysis of obesity-related phenotypes: association of weight with the *MGAT1* gene. *Obesity (Silver Spring).* 2010; 18:803–8. [PubMed: 19851299]
24. Spracklen CN, et al. Association analyses of East Asian individuals and trans-ancestry analyses with European individuals reveal new loci associated with cholesterol and triglyceride levels. *Hum Mol Genet.* 2017; 26:1770–1784. [PubMed: 28334899]
25. Lee D, et al. A method to predict the impact of regulatory variants from DNA sequence. *Nat Genet.* 2015; 47:955–61. [PubMed: 26075791]
26. Do R, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. *Nat Genet.* 2013; 45:1345–52. [PubMed: 24097064]
27. Rosenson RS, Davidson MH, Hirsh BJ, Kathiresan S, Gaudet D. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. *J Am Coll Cardiol.* 2014; 64:2525–40. [PubMed: 25500239]
28. Helgadottir A, et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. *Nat Genet.* 2016; 48:634–9. [PubMed: 27135400]
29. Voight BF, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. *Lancet.* 2012; 380:572–80. [PubMed: 22607825]
30. Zhang Y, et al. Rare coding variants and breast cancer risk: evaluation of susceptibility Loci identified in genome-wide association studies. *Cancer Epidemiol Biomarkers Prev.* 2014; 23:622–8. [PubMed: 24470074]
31. Goldstein JI, et al. zCall: a rare variant caller for array-based genotyping: genetics and population analysis. *Bioinformatics.* 2012; 28:2543–5. [PubMed: 22843986]
32. Liu DJ, et al. Meta-analysis of gene-level tests for rare variant association. *Nat Genet.* 2014; 46:200–4. [PubMed: 24336170]


33. Feng S, Liu D, Zhan X, Wing MK, Abecasis GR. RAREMETAL: fast and powerful meta-analysis for rare variants. *Bioinformatics*. 2014; 30:2828–9. [PubMed: 24894501]
34. Lu X, et al. Coding-sequence variants are associated with blood lipid levels in 14,473 Chinese. *Hum Mol Genet*. 2016; 25:4107–4116. [PubMed: 27516387]
35. Lu X, et al. Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. *Nat Genet*. 2012; 44:890–4. [PubMed: 22751097]
36. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genome wide association scans. *Bioinformatics*. 2010; 26:2190–1. [PubMed: 20616382]
37. GenSalt Collaborative Research G. GenSalt: rationale, design, methods and baseline characteristics of study participants. *J Hum Hypertens*. 2007; 21:639–46. [PubMed: 17443206]
38. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res*. 2010; 38:e164. [PubMed: 20601685]
39. Thurman RE, et al. The accessible chromatin landscape of the human genome. *Nature*. 2012; 489:75–82. [PubMed: 22955617]







**Figure 2. Proportion of total trait variance explained by the significant and coding variants**  
 The variances explained by all the variants reaching exome-wide significance ( $P < 4.5 \times 10^{-7}$ ), and together with the variants at suggestive significance ( $P < 4.46 \times 10^{-6}$ ) are presented with light blue and purple bars, respectively. The proportions of variance explained by the corresponding protein-altering variants are represented by dark blue and purple bars, respectively. The proportions of variance explained by GWAS index variants are represented by yellow bars.



**Figure 3. Effect Size vs. Allele Frequency for variants associated with blood lipids at exome-wide significance**

The protein-altering variants are shown in red in comparison to the non-coding variants shown in black. East Asian-specific protein-altering variants are labeled in diamond. The variants shown in triangle, *PCSK9* (p.Arg93Cys) and *APOA5* (p.Gly185Cys), have extremely rare minor allele frequencies in Europeans, although they do not display population-specific association. The protein-altering variants show strong effects on lipid levels (beta > 0.20 SD units) are highlighted. Estimated power curves are shown (as dashed lines) for the minimum standardized effect sizes (in s.d. units) that could be identified for a given effect-allele frequency with 10% (purple), 50% (green) and 80% (blue) power, assuming sample size 47,532 and alpha level  $4.5 \times 10^{-7}$ .

**Table 1**

Genetic variants at novel loci associated with lipid levels in East Asian samples

Gene	rsID	Position	Alleles	Variants	Trait	AAF	BETA	S.E.	P	N	GLGC			Combined		
											AAF	P	I <sup>2</sup>	AAF	P	I <sup>2</sup>
<i>ACVR1C</i>	rs4377290	2:158437683	C/T		TC	0.33	-0.039	0.007	4.69×10 <sup>-8</sup>	46,025	0.46	1.59×10 <sup>-4</sup>	0.44	6.06×10 <sup>-8</sup>	16.2%	
<i>MCU</i>	rs7901016	10:74637326	C/T		LDL-C	0.27	-0.044	0.008	5.12×10 <sup>-9</sup>	44,985	0.09	1.80×10 <sup>-3</sup>	0.12	2.21×10 <sup>-9</sup>	18.2%	
<i>CD163</i>	rs4883263	12:7649484	C/T	p.Ile342Val	HDL-C	0.69	-0.047	0.007	5.24×10 <sup>-11</sup>	47,456	0.94	6.68×10 <sup>-5</sup>	0.90	6.30×10 <sup>-13</sup>	2.38%	

AAF, alternative allele frequency.

Position is reported in human genome build hg19.

Alleles are listed as alternative/reference allele on the forward strand of the reference genome.

**Table 2**  
Variants at novel loci associated with lipid levels identified from combined East Asian and GLGC samples

Gene	rsID	Position	Alleles	Variants	Trait	Combined					GLGC			East Asian	
						AAF	BETA	S.E.	P	N	I <sup>2</sup>	AAF	P	AAF	P
<i>PDGFC</i>	rs4691380	4:157720124	T/C		HDL-C	0.35	0.014	0.003	1.07×10 <sup>-7</sup>	335,481	0.54%	0.36	2.80×10 <sup>-7</sup>	0.31	0.14
<i>FAM114A2</i>	rs2578377	5:153413390	T/C	p.Gly122Ser	HDL-C	0.67	-0.014	0.003	1.74×10 <sup>-7</sup>	335,481	4.25%	0.63	2.35×10 <sup>-7</sup>	0.87	0.36
<i>MGAT1</i>	rs634501	5:180218668	G/A	p.Leu435Pro	HDL-C	0.72	-0.015	0.003	9.36×10 <sup>-8</sup>	337,027	1.70%	0.76	2.35×10 <sup>-5</sup>	0.52	3.96×10 <sup>-4</sup>
<i>ASCC3</i>	rs9390698	6:101296389	A/G	p.Leu146Phe	LDL-C	0.39	0.014	0.003	5.84×10 <sup>-8</sup>	331,991	0.40%	0.41	1.15×10 <sup>-6</sup>	0.26	1.18×10 <sup>-2</sup>
					TC	0.39	0.015	0.003	5.22×10 <sup>-9</sup>	358,251	0.70%	0.41	1.89×10 <sup>-7</sup>	0.26	5.05×10 <sup>-3</sup>
<i>LOC100996634</i>	rs884366	6:109574095	A/G		HDL-C	0.31	-0.015	0.003	1.45×10 <sup>-8</sup>	327,673	0.04%	0.30	4.06×10 <sup>-6</sup>	0.38	1.88×10 <sup>-4</sup>
<i>EEPD1</i>	rs4302748	7:36191699	A/G		LDL-C	0.18	0.018	0.003	2.10×10 <sup>-8</sup>	333,359	4.30%	0.20	5.55×10 <sup>-7</sup>	0.09	3.82×10 <sup>-3</sup>
<i>PLCE1</i>	rs2274224	10:96039597	C/G	p.Arg1575Pro	TC	0.44	-0.020	0.004	9.92×10 <sup>-8</sup>	150,798	17.73%	0.44	2.80×10 <sup>-7</sup>	0.56	0.41
<i>EIF4B</i>	rs7306523	12:53393964	G/A		LDL-C	0.70	-0.017	0.003	1.38×10 <sup>-7</sup>	313,750	1.10%	0.77	1.75×10 <sup>-5</sup>	0.29	1.27×10 <sup>-3</sup>
					TC	0.70	-0.017	0.003	5.36×10 <sup>-8</sup>	338,266	0.00%	0.77	1.42×10 <sup>-6</sup>	0.29	1.15×10 <sup>-2</sup>
<i>SLC17A8</i>	rs7965082	12:100800193	T/C		LDL-C	0.52	-0.013	0.002	9.21×10 <sup>-8</sup>	333,359	0.00%	0.54	1.89×10 <sup>-6</sup>	0.41	1.31×10 <sup>-2</sup>
					TC	0.52	-0.014	0.002	8.28×10 <sup>-9</sup>	358,251	0.00%	0.54	1.47×10 <sup>-6</sup>	0.41	3.86×10 <sup>-4</sup>

AAF, alternative allele frequency.

Position is reported in human genome build hg19.

Alleles are listed as alternative/reference allele on the forward strand of the reference genome.

Table 3

Inter-ancestry allelic heterogeneity at lipid genes.

Gene	Study	rsID	Note*	Position	Variants	Alleles	Trait	BETA	S.E.	P	Protein-altering variants			Look-up in the other sample	
											AAF	Variance Explained	AAF	AAF	P
<i>PCSK9</i>	GLGC	rs11591147	Protein-altering is top	1:55505647	p.Arg46Leu	T/G	LDL-C	-0.475	0.011	0.00	1.48%	0.70%	0.01%	0.26	
	Asian	rs151193009	Protein-altering is top	1:55509585	p.Arg93Cys	T/C	LDL-C	-0.542	0.029	$7.62 \times 10^{-77}$	1.32%	0.77%	0.01%	$7.62 \times 10^{-9}$	
<i>APOB</i>	GLGC	rs1367117	Explaining index	2:21263900	p.Thr98Ile	A/G	LDL-C	0.105	0.003	$3.61 \times 10^{-278}$	28.44%	0.43%	13.01%	$4.26 \times 10^{-10}$	
	Asian	rs13306194	Protein-altering is top	2:21252534	p.Arg532Trp	A/G	LDL-C	-0.098	0.010	$9.53 \times 10^{-22}$	12.45%	0.20%	0.20%	$8.13 \times 10^{-3}$	
<i>CD36</i>	GLGC	rs3211938	Protein-altering is top	7:80300449	p.Tyr325*	G/T	HDL-C	0.181	0.021	$1.43 \times 10^{-18}$	0.47%	0.03%	0.001%	0.87	
	Asian	rs148910227	Protein-altering is top	7:80302116	p.Arg386Trp	T/C	HDL-C	0.342	0.058	$3.17 \times 10^{-9}$	0.31%	0.07%	0.02%	0.01	
<i>ABCA1</i>	GLGC	rs146292819	Independent of index	9:107556776	p.Asn1800His	G/T	HDL-C	-0.843	0.059	$3.99 \times 10^{-46}$	0.05%	0.07%	0.00%	NA	
	Asian	rs2230808	Independent of index	9:107562804	p.Lys1587Arg	C/T	HDL-C	0.047	0.007	$2.49 \times 10^{-12}$	60.97%	0.10%	72.96%	$9.78 \times 10^{-19}$	
<i>CETP</i>	GLGC	rs5880	Independent of index	16:57015091	p.Ala330Pro	C/G	HDL-C	-0.258	0.007	$4.08 \times 10^{-321}$	4.81%	0.60%	0.64%	$6.90 \times 10^{-7}$	
	Asian	rs2303790	Independent of index	16:57017292	p.Asp459Gly	G/A	HDL-C	0.407	0.025	$7.53 \times 10^{-62}$	2.23%	0.72%	0.02%	$3.16 \times 10^{-5}$	
<i>PMFBP1</i>	GLGC	rs34832584	Independent of index	16:72162966	p.Thr505Lys	T/G	TC	0.020	0.003	$1.62 \times 10^{-8}$	15.93%	0.01%	2.57%	0.50	
	Asian	rs16973716	Explaining index	16:72156842	p.Lys768Asn	G/T	TC	0.042	0.008	$1.75 \times 10^{-7}$	28.96%	0.07%	44.69%	$2.66 \times 10^{-7}$	
<i>LIPG</i>	GLGC	rs77960347	Independent of index	18:47109955	p.Asn396Ser	G/A	HDL-C	0.259	0.012	$1.62 \times 10^{-98}$	1.07%	0.14%	0.01%	0.79	
	Asian	rs2000813	Independent of index	18:47093864	p.Thr111Ile	T/C	HDL-C	0.043	0.007	$1.04 \times 10^{-9}$	31.06%	0.08%	28.61%	$1.76 \times 10^{-41}$	
<i>LDLR</i>	GLGC	rs139043155	Independent of index	19:11217344	p.Asp225Glu	A/T	LDL-C	1.644	0.214	$1.53 \times 10^{-14}$	0.004%	0.02%	0.00%	NA	
	Asian	rs200990725	Protein-altering is top	19:11217315	p.Arg257Trp	T/C	LDL-C	0.882	0.109	$6.35 \times 10^{-16}$	0.094%	0.15%	0.001%	$1.96 \times 10^{-4}$	
<i>PPARA</i>	GLGC	rs1042311	Protein-altering is top	22:46627780	p.Ala268Val	T/C	TC	0.123	0.018	$7.40 \times 10^{-12}$	0.50%	0.01%	0.01%	0.23	
	Asian	rs1800234	Protein-altering is top	22:46615880	p.Val227Ala	C/T	TG	-0.094	0.018	$3.17 \times 10^{-7}$	4.21%	0.07%	0.15%	0.12	

AAF, alternative allele frequency.

Position is reported in human genome build hg19.

Alleles are listed as alternative / reference allele on the forward strand of the reference genome.

\* Protein-altering is top: protein-altering variants are the most significant variants in the known loci.

Explaining index: Conditional on the coding variants, the adjusted *P* for index variants > 0.01.Independent of index: Conditional on the index variants, the adjusted *P* for coding variants with exome-wide significance.

**Table 4**  
Loci where East Asian and GLGC samples identified the same putatively functional protein-altering variant

Gene	rsID	Position	Variant	Alleles	Trait	Study	BETA	S.E.	P	AAF	Variance Explained	Note*
<i>GCKR</i>	rs1260326	2:27730940	p.Leu446Pro	C/T	TG	GLGC	-0.121	0.003	0.00	0.628	0.64%	Protein-altering is top
					TG	Asian	-0.114	0.007	1.26×10 <sup>-62</sup>	0.496	0.64%	Protein-altering is top
<i>MLXIPL</i>	rs35332062	7:73012042	p.Ala358Val	A/G	TG	GLGC	-0.124	0.004	5.22×10 <sup>-205</sup>	0.117	0.30%	Protein-altering is top
					TG	Asian	-0.109	0.011	2.03×10 <sup>-23</sup>	0.109	0.23%	Explaining index
<i>LPL</i>	rs328	8:19819724	p.Ser474*	G/C	TG	GLGC	-0.184	0.004	0.00	0.098	0.58%	Explaining index
					TG	Asian	-0.169	0.012	1.93×10 <sup>-45</sup>	0.095	0.46%	Explaining index
<i>GPM</i>	rs2792751	10:113940329	p.Ile43Val	C/T	TC	GLGC	-0.028	0.003	7.14×10 <sup>-22</sup>	0.728	0.03%	Explaining index
					TC	Asian	-0.043	0.007	5.67×10 <sup>-9</sup>	0.706	0.07%	Protein-altering is top
<i>HNF1A</i>	rs1169288	12:121416650	p.Ile27Leu	C/A	TC	GLGC	0.037	0.003	9.99×10 <sup>-40</sup>	0.333	0.06%	Protein-altering is top
					TC	Asian	0.038	0.007	4.86×10 <sup>-8</sup>	0.404	0.07%	Protein-altering is top
<i>TMS6SF2</i>	rs58542926	19:19379549	p.Glu167Lys	T/C	TC	GLGC	-0.129	0.005	7.03×10 <sup>-155</sup>	0.074	0.22%	Protein-altering is top
					TC	Asian	-0.066	0.013	4.25×10 <sup>-7</sup>	0.070	0.06%	Protein-altering is top
<i>APOE</i>	rs7412	19:45412079	p.Arg176Cys	T/C	LDL-C	GLGC	-0.539	0.006	0.00	0.075	3.80%	Independent of index
					LDL-C	Asian	-0.472	0.016	4.87×10 <sup>-197</sup>	0.088	3.49%	Protein-altering is top

AAF, alternative allele frequency.

Position is reported in human genome build hg19.

Alleles are listed as alternative / reference allele on the forward strand of the reference genome.

\* Protein-altering is top: protein-altering variants are the most significant variants in the known loci.

Explaining index: Conditional on the coding variants, the adjusted *P* for index variants >0.01.

Independent of index: Conditional on the index variants, the adjusted *P* for coding variants with exome-wide significance.

Table 5

East Asian-specific variants associated with blood lipids (Conditional  $P < 4.5 \times 10^{-7}$ )

Gene	Position	rsID	Alleles	Variant	Trait	East Asian						GLGC			
						AAF	BETA	S.E.	P	P <sub>adj</sub>	AAF	BETA	S.E.	P	
<i>EVF5</i>	1:93159927	rs117711462	A/G	p.Arg354Cys	TC	0.69%	0.212	0.040	1.41×10 <sup>-7</sup>	2.15×10 <sup>-7</sup>	0.03%	0.097	0.080	0.245	
<i>APOB</i>	2:21228437	rs376825639	G/A	p.Ile3768Thr	TC	0.15%	-0.659	0.097	8.44×10 <sup>-12</sup>	9.96×10 <sup>-12</sup>					
	2:21252807	noRS	T/C	p.Cys478Tyr	LDL-C	0.15%	-0.579	0.098	3.35×10 <sup>-9</sup>	4.44×10 <sup>-9</sup>					
	2:21252534	rs13306194	A/G	p.Arg532Trp	LDL-C	0.09%	-0.876	0.138	2.08×10 <sup>-10</sup>	1.65×10 <sup>-10</sup>					
<i>HMGCR</i>	5:74646765	rs191835914	C/A	p.Tyr311Ser	TC	12.39%	-0.114	0.010	1.45×10 <sup>-29</sup>	2.01×10 <sup>-17</sup>	0.19%	-0.084	0.031	6.74×10 <sup>-3</sup>	
<i>CD36</i>	7:80302116	rs148910227	T/C	p.Arg386Trp	LDL-C	12.45%	-0.098	0.010	9.53×10 <sup>-22</sup>	2.08×10 <sup>-13</sup>	0.20%	-0.085	0.032	8.13×10 <sup>-3</sup>	
<i>APOA1</i>	11:116707736	rs12718465	T/C	p.Ala61Thr	TG	12.43%	-0.073	0.010	1.38×10 <sup>-12</sup>	4.96×10 <sup>-15</sup>	0.19%	-0.133	0.032	2.96×10 <sup>-5</sup>	
<i>ACACB</i>	12:109696838	rs2075260	A/G	p.Val214Ile	LDL-C	1.73%	-0.190	0.026	2.20×10 <sup>-13</sup>	2.68×10 <sup>-9</sup>	0.04%	-0.117	0.067	0.079	
<i>ALDH2</i>	12:112241766	rs671	A/G	p.Glu457Lys	HDL-C	0.31%	0.342	0.058	3.17×10 <sup>-9</sup>	3.60×10 <sup>-9</sup>	0.02%	0.215	0.084	0.010	
<i>CETP</i>	16:56997025	rs201790757	G/T	p.Tyr74*	TG	74.34%	0.043	0.008	3.95×10 <sup>-8</sup>	7.64×10 <sup>-8</sup>	80.23%	0.011	0.003	5.32×10 <sup>-4</sup>	
<i>PKDIL3</i>	16:57017292	rs2303790	G/A	p.Asp459Gly	HDL-C	20.43%	-0.048	0.008	1.16×10 <sup>-8</sup>	1.85×10 <sup>-8</sup>	0.08%	-0.005	0.052	0.928	
	16:71967927	rs17358402	T/C	p.Arg1572His	LDL-C	0.03%	1.117	0.182	8.97×10 <sup>-10</sup>	4.33×10 <sup>-10</sup>	0.001%	0.719	0.352	0.041	
<i>LDLR</i>	19:11217315	rs200990725	T/C	p.Arg257Trp	TC	5.40%	0.085	0.015	2.11×10 <sup>-8</sup>	1.86×10 <sup>-9</sup>	24.44%	-0.013	0.003	8.47×10 <sup>-5</sup>	
<i>PPARA</i>	22:46615880	rs1800234	C/T	p.Val227Ala	LDL-C	5.41%	0.088	0.015	1.96×10 <sup>-9</sup>	1.40×10 <sup>-10</sup>	24.44%	-0.009	0.003	3.72×10 <sup>-3</sup>	
					TG	0.09%	0.677	0.109	5.57×10 <sup>-10</sup>	5.00×10 <sup>-9</sup>	0.001%	1.897	0.502	1.57×10 <sup>-4</sup>	
						0.09%	0.882	0.109	6.35×10 <sup>-16</sup>	6.15×10 <sup>-15</sup>	0.001%	1.869	0.502	1.96×10 <sup>-4</sup>	
						4.21%	-0.094	0.018	3.17×10 <sup>-7</sup>	3.36×10 <sup>-7</sup>	0.15%	-0.058	0.037	0.118	

AAF, alternative allele frequency.

Position is reported in human genome build hg19.

Alleles are listed as alternative / reference allele on the forward strand of the reference genome.

P<sub>adj</sub>, conditioning on the independent variants in the corresponding loci identified by GLGC exome-wide association studies (Supplementary Table 11).